Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Time to See Results
Stone NL, England TJ, OSullivan SE
If you have hypertension and are considering GLP-1 therapy, understanding your current blood pressure control, medication interactions, and underlying cardiovascular risk becomes critical
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
US$ 29.97
US$ 23.29
US$ 27.59
US$ 28.85
US$ 21.04
US$ 20.16
